Article Correctness Is Author's Responsibility: Extended Interval Dosing of Natalizumab Does Not Reduce Efficacy in MS

The article below may contain offensive and/or incorrect content.

Extended interval dosing of natalizumab may also be associated with reduced risk for progressive multifocal leukoencephalopathy.